Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 3/20 | 0.34 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17110393 | 0.89 | PRMT1 (0.38) | PRMT1LMNAPOLBTRPV4KDM4E | |
| SCHEMBL17098046 | 0.86 | TRPC1 (0.38) | PRMT1LMNAPOLBKDM4EALDH1A1 | |
| SCHEMBL17098049 | 0.86 | TRPC1 (0.38) | PRMT1LMNAPOLBKDM4EALDH1A1 | |
| SCHEMBL17110437 | 0.84 | TRPV4 (0.38) | TRPV4 | |
| SCHEMBL17048838 | 0.83 | PRMT1 (0.36) | PRMT1LMNAPOLBKDM4EHSD17B10 | |
| SCHEMBL17099119 | 0.83 | LMNA (0.40) | PRMT1LMNAKDM4EHSD17B10ALDH1A1 | |
| SCHEMBL17099121 | 0.83 | LMNA (0.40) | PRMT1LMNAKDM4EHSD17B10ALDH1A1 | |
| SCHEMBL17048835 | 0.83 | PRMT1 (0.36) | PRMT1LMNAPOLBKDM4EHSD17B10 | |
| SCHEMBL17097527 | 0.81 | LMNA (0.50) | LMNAPOLBKDM4EHSD17B10ALDH1A1 | |
| SCHEMBL17097525 | 0.81 | LMNA (0.50) | LMNAPOLBKDM4EHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365522-B2 | Pyrazole amide derivative | AMGEN INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20150266824-A1 | Pyrazole Amide Derivative | TEIJIN LIMITED (JP) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266824-A1 | Pyrazole Amide Derivative | RORC, RORB, RORA | PRMT1 348/4885LMNA 4719/4885POLB 4102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.